Researchers Study CAR-T Therapy Response Mechanisms
The collaboration aims to identify predictive biomarkers to improve clinical outcomes for non-Hodgkin lymphoma patients.
Updated on Oct. 22, 2026 in Biotech
Live Poll
Do you believe integrating AI into clinical cancer research will improve patient treatment outcomes?
BostonGene and the Medical University of South Carolina have launched a research collaboration to analyze CAR-T therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. This research-stage partnership utilizes multiomics data to study immune dynamics associated with treatment response and toxicity.
Why it matters
By connecting molecular changes to clinical outcomes, the team aims to identify predictive biomarkers that could improve patient selection and manage treatment risks. This work addresses critical challenges in durability and toxicity for cell-based therapies.
Preliminary phase Ib trial data recorded a 67% complete remission rate for treated patients. No grade 3+ cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome cases were observed during the study.
The players
BostonGene
A biotech company providing a biologically grounded AI platform for multiomics integration and immune system modeling.
Medical University of South Carolina
A research university based in South Carolina that hosts the clinical trial site for the CAR-T therapy study.
The details
The collaboration employs an AI platform to model immune system dynamics by integrating multiomics data, including bulk RNA sequencing—the analysis of all RNA in a tissue sample to identify gene expression levels—and high-throughput multi-colour flow cytometry. Researchers found that treatment response is linked to CD8 effector memory cells, while disease progression is tied to baseline T-cell exhaustion.
Timeline
October 22, 2026: The research collaboration was officially announced.
2026: Preliminary trial data was presented at ASCO 2026.
The Tech Race
This partnership formalizes an effort to move beyond empirical clinical results toward a mechanism-based understanding of CAR-T performance. It places the group in the cohort of researchers aiming to solve the persistence and toxicity barriers defining the current generation of cell therapies.
The study is currently restricted to patients with relapsed or refractory CD19 B-cell non-Hodgkin lymphoma participating in the phase Ib trial at the Medical University of South Carolina. Outcomes from this work will inform future clinical screening protocols and patient eligibility criteria for similar cell-based treatments.
The takeaway
This collaboration seeks to translate multiomics data into clinical tools for predicting treatment response. Interested parties should monitor subsequent peer-reviewed findings for the formal validation of the biomarkers linked to CD8 effector memory cell activity.
Further reading
Explore ongoing advancements in the field of Biotech.
Source note: This article includes information reported by Pharmabiz.
Live Poll
Do you believe integrating AI into clinical cancer research will improve patient treatment outcomes?
